Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.

Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.

Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.

Abstract: A pyrotechnic composition includes a fuel, an oxidizer, flow and rate control agents and oleoresin capsicum as an irritant. The composition is useful in crowd control products. The composition contains rate control ingredients to maintain combustion at a temperature below the point of degradation of the oleoresin capsicum, balanced with a booster material to maintain combustion.

Abstract: Human ?2-antiplasmin (?2AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of ?2AP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or ?2APpro and an N-terminally-shortened 452-residue “activated”-form, or ?2APact. The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than ?2APpro and makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of ?2APpro to yield ?2APact. This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE). Novel inhibitors of circulating APCE can diminish ?2AP inhibitory capacity within forming fibrin or blood clots thereby making fibrin deposits or blood clots more susceptible to removal by plasmin.

Abstract: The present invention is directed toward inhibitors of antiplasmin cleaving enzyme for use in various therapies related to fibrin and ?2-antiplasmin, and to substrates of APCE, which may be used, for example, in screening methods for identifying such inhibitors. The present invention is further directed to methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the rations of types of plasma ?2-antiplasmin.